Captain T Cell

Captain T Cell develops first-in-class, efficacy-enhanced T cell therapies against solid tumors that are not addressed by existing treatments. Captain T Cell generates next-generation TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In addition, the company has established a novel allogeneic platform to enable off-the-shelf treatments of solid tumors. Captain T Cell is based in Schoenefeld/Berlin, Germany, and backed by leading European investors i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H. Captain T Cell was founded by a dedicated team of immuno-oncology experts using technology developed at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.